- Report
- February 2026
- 250 Pages
Global
From €4026EUR$4,490USD£3,440GBP
- Report
- January 2026
Global
From €4393EUR$4,900USD£3,754GBP
- Report
- February 2026
- 250 Pages
Global
From €4026EUR$4,490USD£3,440GBP
- Report
- November 2025
- 182 Pages
Global
From €4035EUR$4,500USD£3,447GBP
- Report
- November 2025
- 200 Pages
Global
From €7128EUR$7,950USD£6,091GBP
- Report
- May 2026
- 154 Pages
Global
From €3542EUR$3,950USD£3,026GBP
- Report
- November 2025
- 150 Pages
Global
From €4349EUR$4,850USD£3,716GBP
- Report
- February 2026
- 133 Pages
Global
From €3500EUR$4,182USD£3,095GBP
- Report
- November 2021
- 222 Pages
Global
From €2690EUR$3,000USD£2,298GBP
- Report
- July 2022
- 263 Pages
Global
From €1800EUR$2,151USD£1,592GBP
- Report
- July 2022
- 165 Pages
Global
From €5335EUR$5,950USD£4,558GBP
- Report
- August 2025
- 192 Pages
Global
From €3179EUR$3,545USD£2,716GBP
€3532EUR$3,939USD£3,018GBP
- Report
- July 2023
- 145 Pages
Global
From €2824EUR$3,150USD£2,413GBP
- Report
- March 2024
- 200 Pages
Global
From €3721EUR$4,150USD£3,179GBP
- Report
- October 2024
- 87 Pages
Spain
From €3138EUR$3,500USD£2,681GBP
- Report
- November 2023
- 81 Pages
Germany
From €3138EUR$3,500USD£2,681GBP
- Report
- October 2023
- 81 Pages
Japan
From €3138EUR$3,500USD£2,681GBP
- Report
- November 2023
- 90 Pages
France
From €3138EUR$3,500USD£2,681GBP
- Clinical Trials
- April 2025
- 450 Pages
Global
From €4483EUR$5,000USD£3,831GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €1121EUR$1,250USD£958GBP

The B Cell Maturation Antigen (BCMA) market is a subset of the oncology drugs market. BCMA is a protein found on the surface of B cells, a type of white blood cell. BCMA is a promising target for cancer immunotherapy, as it is expressed on multiple myeloma cells and other B-cell malignancies. BCMA-targeted therapies are designed to stimulate the body's immune system to recognize and attack cancer cells.
BCMA-targeted therapies are being developed by a number of companies, including Amgen, Bristol-Myers Squibb, Celgene, Gilead Sciences, and Novartis. These companies are researching and developing BCMA-targeted therapies for multiple myeloma and other B-cell malignancies. Additionally, several clinical trials are underway to evaluate the safety and efficacy of BCMA-targeted therapies. Show Less Read more